RETRACTED: NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer (Retracted article. See vol. 18, pg. 3943, 2022)

被引：17

作者：

Bai, Rui ^{[1
]}

Yuan, Cheng ^{[1
]}

Sun, Wenjie ^{[1
]}

Zhang, Jianguo ^{[1
]}

Luo, Yuan ^{[1
]}

Gao, Yanping ^{[1
]}

Li, Yangyi ^{[1
]}

Gong, Yan ^{[2
,3
]}

Xie, Conghua ^{[1
,4
,5
]}

机构：

[1] Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China

[2] Wuhan Univ, Zhongnan Hosp, Dept Biol Repositories, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China

[3] Wuhan Univ, Tumor Precis Diag & Treatment Technol & Translat, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China

[4] Wuhan Univ, Hubei Key Lab Tumour Biol Behav, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China

[5] Wuhan Univ, Hubei Canc Clin Study Ctr, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China

来源：

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2021年 / 17卷 / 08期

基金：

中国国家自然科学基金;

关键词：

NEK2; NSCLC; tumorigenesis; Wnt/beta-catenin; tumor microenvironment; DRUG-RESISTANCE; POOR-PROGNOSIS; IMMUNOTHERAPY; EXPRESSION; OVEREXPRESSION; PROLIFERATION; POLARIZATION; SENSITIVITY; PROGRESSION; ACTIVATION;

D O I：

10.7150/ijbs.59019

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Abnormal expression and dysfunction of Never-in-mitosis-A-related kinase 2 (NEK2) result in tumorigenesis. High levels of NEK2 are related to malignant progression, drug resistance, and poor prognosis. However, the relationship between NEK2 levels and the occurrence of non-small cell lung cancer (NSCLC) remains unknown. This study aimed to explore the impacts of NEK2 on the oncogenesis of NSCLC and the tumor microenvironment. Downregulation of NEK2 inhibited A549 and H1299 cell proliferation, migration, and invasion, blocking cell cycle at the GO/G1 phase. Loss of NEK2 inhibited the release of IL-10 from tumor cells, M2-like polarization of macrophages, angiogenesis, and vascular endothelial cell migration. Furthermore, NEK2 deficiency inhibited tumor growth in vivo. Taken together, NEK2 knockdown inhibited the occurrence and development of NSCLC, M2 polarization of macrophages, and angiogenesis. The abnormal expression of NEK2 might not only indicate tumor progression and patient prognosis but also serve as a potential molecular therapeutic target with great development prospects.

引用

页码：1995 / 2008

页数：14

共 49 条

[1] Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue [J].

Burger, PE ;

Xiong, XH ;

Coetzee, S ;

Salm, SN ;

Moscatelli, D ;

Goto, K ;

Wilson, EL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (20) :7180-7185

[2] Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) [J].

Chae, Young Kwang ;

Arya, Ayush ;

Iams, Wade ;

Cruz, Marcelo R. ;

Chandra, Sunandana ;

Choi, Jaehyuk ;

Giles, Francis .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[3] microRNA-128-3p overexpression inhibits breast cancer stem cell characteristics through suppression of Wnt signalling pathway by down-regulating NEK2 [J].

Chen, Yuanwen ;

Wu, Nian ;

Liu, Lei ;

Dong, Huaying ;

Liu, Xinao .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (13) :7353-7369

[4] Immunotherapy in Lung Cancer: A New Age in Cancer Treatment [J].

Corrales, Luis ;

Scilla, Katherine ;

Caglevic, Christian ;

Miller, Ken ;

Oliveira, Julio ;

Rolfo, Christian .

IMMUNOTHERAPY, 2ND EDITION, 2018, 995 :65-95

[5] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[6] Non-Small Cell Lung Cancer [J].

Ettinger, David S. ;

Akerley, Wallace ;

Borghaei, Hossein ;

Chang, Andrew C. ;

Cheney, Richard T. ;

Chirieac, Lucian R. ;

D'Amico, Thomas A. ;

Demmy, Todd L. ;

Ganti, Apar Kishor P. ;

Govindan, Ramaswamy ;

Grannis, Frederic W., Jr. ;

Horn, Leora ;

Jahan, Thierry M. ;

Jahanzeb, Mohammad ;

Kessinger, Anne ;

Komaki, Ritsuko ;

Kong, Feng-Ming ;

Kris, Mark G. ;

Krug, Lee M. ;

Lennes, Inga T. ;

Loo, Billy W., Jr. ;

Martins, Renato ;

O'Malley, Janis ;

Osarogiagbon, Raymond U. ;

Otterson, Gregory A. ;

Patel, Jyoti D. ;

Pinder-Schenck, Mary C. ;

Pisters, Katherine M. ;

Reckamp, Karen ;

Riely, Gregory J. ;

Rohren, Eric ;

Swanson, Scott J. ;

Wood, Douglas E. ;

Yang, Stephen C. ;

Hughes, Miranda ;

Gregory, Kristina M. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (10) :1236-1271

[7] Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 [J].

Ferlay, J. ;

Colombet, M. ;

Soerjomataram, I. ;

Dyba, T. ;

Randi, G. ;

Bettio, M. ;

Gavin, A. ;

Visser, O. ;

Bray, F. .

EUROPEAN JOURNAL OF CANCER, 2018, 103 :356-387

[8] M1 and M2 Monocytes in Rheumatoid Arthritis: A Contribution of Imbalance of M1/M2 Monocytes to Osteoclastogenesis [J].

Fukui, Shoichi ;

Iwamoto, Naoki ;

Takatani, Ayuko ;

Igawa, Takashi ;

Shimizu, Toshimasa ;

Umeda, Masataka ;

Nishino, Ayako ;

Horai, Yoshiro ;

Hirai, Yasuko ;

Koga, Tomohiro ;

Kawashiri, Shin-ya ;

Tamai, Mami ;

Ichinose, Kunihiro ;

Nakamura, Hideki ;

Origuchi, Tomoki ;

Masuyama, Ritsuko ;

Kosai, Kosuke ;

Yanagihara, Katsunori ;

Kawakami, Atsushi .

FRONTIERS IN IMMUNOLOGY, 2018, 8

[9] The potential of antiangiogenic therapy in non-small cell lung cancer [J].

Giaccone, Giuseppe .

CLINICAL CANCER RESEARCH, 2007, 13 (07) :1961-1970

[10] Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients [J].

Hodi, FS ;

Mihm, MC ;

Soiffer, RJ ;

Haluska, FG ;

Butler, M ;

Seiden, MV ;

Davis, T ;

Henry-Spires, R ;

MacRae, S ;

Willman, A ;

Padera, R ;

Jaklitsch, MT ;

Shankar, S ;

Chen, TC ;

Korman, A ;

Allison, JP ;

Dranoff, G .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) :4712-4717

← 1 2 3 4 5 →